Sanofi posts data from contentious phase 2 multiple sclerosis trial

Sanofi posts data from contentious phase 2 multiple sclerosis trial

Source: 
Fierce Biotech
snippet: 

Sanofi has posted the data that led it to start four phase 3 trials of its Principia Biopharma-partnered multiple sclerosis drug SAR442168. The phase 2 linked the BTK inhibitor to relative reductions in new lesions of 85% or more, but criticism of the study design means doubts remain as the program enters the pivotal stage.